Jeff Jones
Stock Analyst at Oppenheimer
(2.10)
# 2,913
Out of 5,111 analysts
96
Total ratings
33.33%
Success rate
-0.15%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $84.19 | +42.53% | 7 | Dec 9, 2025 | |
| PTHS Pelthos Therapeutics | Reiterates: Outperform | $50 → $57 | $21.83 | +161.11% | 2 | Nov 14, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $8.21 | +70.52% | 11 | Oct 27, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $2.06 | +1,113.59% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $8.66 | +512.01% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $23.11 | +90.39% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $11.40 | +119.30% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $4.12 | +312.62% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $7.94 | +114.11% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $36.21 | +137.50% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $4.07 | +342.26% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.18 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.84 | +463.38% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.25 | +3,500.00% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.20 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.16 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.92 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.18 | +1,171.19% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $4.69 | +39,878.68% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $6.09 | +17,962.40% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $84.19
Upside: +42.53%
Pelthos Therapeutics
Nov 14, 2025
Reiterates: Outperform
Price Target: $50 → $57
Current: $21.83
Upside: +161.11%
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $8.21
Upside: +70.52%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $2.06
Upside: +1,113.59%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $8.66
Upside: +512.01%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $23.11
Upside: +90.39%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $11.40
Upside: +119.30%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $4.12
Upside: +312.62%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $7.94
Upside: +114.11%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $36.21
Upside: +137.50%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $4.07
Upside: +342.26%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.18
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.84
Upside: +463.38%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.25
Upside: +3,500.00%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $16.20
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.16
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.92
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.18
Upside: +1,171.19%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $4.69
Upside: +39,878.68%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $6.09
Upside: +17,962.40%